Ipsen Biopharmaceuticals, Inc.
IPSEYNext catalyst
Corabotase
Moderate to Severe Glabellar Lines
Get an email about IPSEY's next catalysts
Track Ipsen Biopharmaceuticals (IPSEY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 5 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline
6 upcoming, 0 past
Corabotase Phase 3 Est. Readout
Estimated primary completion for Corabotase trial (NCT07427797) in Moderate to Severe Glabellar Lines. Topline data typically follows completion by weeks to months.
SourceElafibranor Phase 3 Est. Readout (ELONSEN)
Primary completion for Elafibranor trial (NCT06730061) in Primary Biliary Cholangitis
SourceOdevixibat Phase 3 Est. Readout (ASSERT-EXT)
Primary completion for Odevixibat trial (NCT05035030) in Alagille Syndrome
SourceIPN10200 Phase 2 Est. Readout (CATALPA)
Primary completion for IPN10200 trial (NCT06937931) in Cervical Dystonia
SourceDysport Phase 2 Est. Readout (LANTIC)
Primary completion for Dysport trial (NCT04821089) in Moderate to Severe Upper Facial Lines
SourceIPN10200 Phase 2 Est. Readout (MERANTI)
Primary completion for IPN10200 trial (NCT06625060) in Episodic Migraine
SourceMarket Overview
Stock performance and key metrics
Smecta (Diosmectite)
Diarrhoea
EGb 761® (Tanakan®)
Multiple Sclerosis, Relapsing-Remitting
Odevixibat
Biliary Atresia
Triptorelin pamoate (Decapeptyl® SR)
Precocious Puberty
BLI800
Diagnosis Disease
PEG 4000 (Forlax®)
Chronic Constipation
Triptorelin Pamoate PR 3-month
Endometriosis
A4250 (odevixibat)
Progressive Familial Intrahepatic Cholestasis
Pegvisomant
Acromegaly
Triptorelin embonate
Prostate Cancer
rhIGF-1 (mecasermin, Tercica, Inc.)
Growth Disorders
Botulinum toxin type A
Glabellar Frown Lines
Triptorelin (I.N.N.)
Precocious Puberty
Irinotecan Liposomal Injection
Metastatic Adenocarcinoma of the Pancreas
EGb761
Stroke, Acute
Eziclen®/Izinova®
Digestive System Disease
mecasermin
Growth Hormone Insensitivity Syndrome
Cabozantinib
Esophageal Cancer
Eziclen
Bowel Cleansing
rhIGF-1 (mecasermin) for a period of 86 weeks
Insulin-Like Growth Factor-1 Deficiency
Lanreotide
Carcinoid Syndrome
Lanreotide microparticles
Digestive Fistulae
Somatropin (rDNA origin)
Turner Syndrome
Lanreotide Autogel®
Acromegaly
Lanreotide (microparticle formulation)
Intestinal Obstruction
Triptorelin pamoate (embonate) salt
Advanced Prostate Cancer
Corabotase
Moderate to Severe Glabellar Lines
Somatuline Autogel (lanreotide acetate)
Acromegaly
Elafibranor
Primary Biliary Cholangitis
IPN10200
Moderate to Severe Upper Facial Lines
lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
Acromegaly
lanreotide (Autogel formulation), duration of treatment 46-48 weeks
Acromegaly
Irinotecan liposome injection
Small Cell Lung Cancer
Triptorelin (Decapeptyl®)
Prostate Cancer
Palovarotene
Fibrodysplasia Ossificans Progressiva (FOP)
Lanreotide (Autogel formulation)
Acromegaly
Triptorelin Pamoate
Central Precocious Puberty
Lanreotide Autogel
Intestinal Obstruction
satoreotide trizoxetan
Gastroenteropancreatic Neuroendocrine Tumors
Lanreotide PRF
Acromegaly
IPN01195
Advanced Solid Tumor
nal-IRI
Pancreatic Cancer
IPN60300
Locally Advanced Solid Tumor
BN83495
Endometrial Cancer
Triptorelin Pamoate (Pamorelin® LA)
Prostate Cancer
IPN01203
Advanced Solid Tumor
Dysport
Spasticity
Ritivixibat
Primary Sclerosing Cholangitis
Tasquinimod
Advanced or Metastatic Hepatocellular Cancer
EGb761®
Alzheimer's Disease
IPN10200 dose A
Episodic Migraine
EGb 761
Friedreich Ataxia
Temozolomide (TMZ)
Gastroenteropancreatic Neuroendocrine Tumors
Lanreotide (Autogel formulation) and Temozolomide
Neuroendocrine Tumours
IPN01194
Melanoma
Diflomotecan (BN80915)
Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Smecta (Diosmectite) | Phase 3 | Diarrhoea | - | - |
EGb 761® (Tanakan®) | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
Odevixibat | Phase 3 | Biliary Atresia | - | - |
Triptorelin pamoate (Decapeptyl® SR) | Phase 3 | Precocious Puberty | - | - |
BLI800 | Phase 3 | Diagnosis Disease | - | - |
PEG 4000 (Forlax®) | Phase 3 | Chronic Constipation | - | - |
Triptorelin Pamoate PR 3-month | Phase 3 | Endometriosis | - | - |
A4250 (odevixibat) | Phase 3 | Progressive Familial Intrahepatic Cholestasis | - | - |
Pegvisomant | Phase 3 | Acromegaly | - | - |
Triptorelin embonate | Phase 3 | Prostate Cancer | - | - |
rhIGF-1 (mecasermin, Tercica, Inc.) | Phase 3 | Growth Disorders | - | - |
Botulinum toxin type A | Phase 3 | Glabellar Frown Lines | - | - |
Triptorelin (I.N.N.) | Phase 3 | Precocious Puberty | - | - |
Irinotecan Liposomal Injection | Phase 3 | Metastatic Adenocarcinoma of the Pancreas | - | - |
EGb761 | Phase 3 | Stroke, Acute | - | - |
Eziclen®/Izinova® | Phase 3 | Digestive System Disease | - | - |
mecasermin | Phase 3 | Growth Hormone Insensitivity Syndrome | - | - |
Cabozantinib | Phase 3 | Esophageal Cancer | - | - |
Eziclen | Phase 3 | Bowel Cleansing | - | - |
rhIGF-1 (mecasermin) for a period of 86 weeks | Phase 3 | Insulin-Like Growth Factor-1 Deficiency | - | - |
Lanreotide | Phase 3 | Carcinoid Syndrome | - | - |
Lanreotide microparticles | Phase 3 | Digestive Fistulae | - | - |
Somatropin (rDNA origin) | Phase 3 | Turner Syndrome | - | - |
Lanreotide Autogel® | Phase 3 | Acromegaly | - | - |
Lanreotide (microparticle formulation) | Phase 3 | Intestinal Obstruction | - | - |
Triptorelin pamoate (embonate) salt | Phase 3 | Advanced Prostate Cancer | - | - |
Corabotase | Phase 3 | Moderate to Severe Glabellar Lines | - | - |
Somatuline Autogel (lanreotide acetate) | Phase 3 | Acromegaly | - | - |
Elafibranor | Phase 3 | Primary Biliary Cholangitis | - | - |
IPN10200 | Phase 3 | Moderate to Severe Upper Facial Lines | - | - |
lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval | Phase 3 | Acromegaly | - | - |
lanreotide (Autogel formulation), duration of treatment 46-48 weeks | Phase 3 | Acromegaly | - | - |
Irinotecan liposome injection | Phase 3 | Small Cell Lung Cancer | - | - |
Triptorelin (Decapeptyl®) | Phase 3 | Prostate Cancer | - | - |
Palovarotene | Phase 3 | Fibrodysplasia Ossificans Progressiva (FOP) | - | - |
Lanreotide (Autogel formulation) | Phase 3 | Acromegaly | - | - |
Triptorelin Pamoate | Phase 3 | Central Precocious Puberty | - | - |
Lanreotide Autogel | Phase 3 | Intestinal Obstruction | - | - |
satoreotide trizoxetan | Phase 2 | Gastroenteropancreatic Neuroendocrine Tumors | - | - |
Lanreotide PRF | Phase 2 | Acromegaly | - | - |
IPN01195 | Phase 2 | Advanced Solid Tumor | - | - |
nal-IRI | Phase 2 | Pancreatic Cancer | - | - |
IPN60300 | Phase 2 | Locally Advanced Solid Tumor | - | - |
BN83495 | Phase 2 | Endometrial Cancer | - | - |
Triptorelin Pamoate (Pamorelin® LA) | Phase 2 | Prostate Cancer | - | - |
IPN01203 | Phase 2 | Advanced Solid Tumor | - | - |
Dysport | Phase 2 | Spasticity | - | - |
Ritivixibat | Phase 2 | Primary Sclerosing Cholangitis | - | - |
Tasquinimod | Phase 2 | Advanced or Metastatic Hepatocellular Cancer | - | - |
EGb761® | Phase 2 | Alzheimer's Disease | - | - |
IPN10200 dose A | Phase 2 | Episodic Migraine | - | - |
EGb 761 | Phase 2 | Friedreich Ataxia | - | - |
Temozolomide (TMZ) | Phase 2 | Gastroenteropancreatic Neuroendocrine Tumors | - | - |
Lanreotide (Autogel formulation) and Temozolomide | Phase 2 | Neuroendocrine Tumours | - | - |
IPN01194 | Phase 2 | Melanoma | - | - |
Diflomotecan (BN80915) | Phase 2 | Small Cell Lung Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Ipsen Biopharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 56 drug candidates in Ipsen Biopharmaceuticals, Inc.'s (IPSEY) pipeline across Phase 3, Phase 2. Its lead program is Corabotase (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ipsen Biopharmaceuticals, Inc.'s next FDA catalyst?→
Ipsen Biopharmaceuticals, Inc.'s (IPSEY) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IPSEY biotech catalysts?→
Add IPSEY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ipsen Biopharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.